Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib

Mitochondrial oxidative stress is the achille’s heel of melanoma cells resistant to Braf-mutant inhibitor

(2015) Paola Corazao-Rozas et al.   Oncotarget

CD271 is an imperfect marker for melanoma initiating cells

(2015) Yann Cheli et al.   Oncotarget

PDGFRα up-regulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation

(2015) Francesco Sabbatino et al.   Oncotarget

A stress-induced early innate response causes multidrug tolerance in melanoma

(2014) D Ravindran Menon et al.   ONCOGENE

The Nerve Growth Factor Receptor CD271 Is Crucial to Maintain Tumorigenicity and Stem-Like Properties of Melanoma Cells

(2014) Torben Redmer et al.   PLoS One

The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF 

(2014) M. P. Smith et al.   Cancer Discovery

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

The IκB kinase complex in NF-κB regulation and beyond

(2013) Michael Hinz et al.   EMBO REPORTS

Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner

(2013) M. Cerezo et al.   MOLECULAR CANCER THERAPEUTICS

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

(2012) Jennifer Landsberg et al.   NATURE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human CD271-Positive Melanoma Stem Cells Associated with Metastasis Establish Tumor Heterogeneity and Long-term Growth

(2011) G. Civenni et al.   CANCER RESEARCH

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metformin inhibits melanoma development through autophagy and apoptosis mechanisms

(2011) T Tomic et al.   Cell Death & Disease

Cell-Selective Inhibition of NF- B Signaling Improves Therapeutic Index in a Melanoma Chemotherapy Model

(2011) T. Enzler et al.   Cancer Discovery

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth

(2010) T Botton et al.   CELL DEATH AND DIFFERENTIATION

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

(2010) Alexander D. Boiko et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

The MAPK pathway in melanoma

(2009) Leslie A Fecher et al.   CURRENT OPINION IN ONCOLOGY

In Vitro and In Vivo Anti-Melanoma Effects of Ciglitazone

(2009) Thomas Botton et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Identification of cells initiating human melanomas

(2008) Tobias Schatton et al.   NATURE